Introduction
============

Transparency in designing, conducting, and reporting of human experiments and observational studies is essential to guarantee the integrity of clinical research.[@b1-cpaa-2-169] Registration of clinical trials with information about study sponsors and protocols makes clinical research more transparent. In 2000, the National Institutes of Health (NIH) requested that clinical trials assessing pharmacologic treatments for serious or life-threatening diseases be registered in the ClinicalTrials.gov online database. This website was developed by the National Library of Medicine as an information service for the NIH and the US Department of Health and Human Services.[@b2-cpaa-2-169] However, at that time, NIH policy did not require mandatory registration of all human studies. In 2005, the World Association of Medical Editors started to require mandatory registration of all clinical studies as a condition of publication.[@b3-cpaa-2-169] Sponsors must now provide the World Health Organization (WHO) with a minimum dataset of information, including details of study design, recruitment activities, ethics review of research, target sample size, conditions of eligibility for subjects to participate in the study, and primary and secondary outcomes.[@b4-cpaa-2-169] Stakeholders can find detailed information about study protocols on ClinicalTrials.gov, but study results are not yet consistently available online.

Selective publication of positive results and outcomes[@b5-cpaa-2-169]--[@b7-cpaa-2-169] led to further scrutiny and called for public disclosure of study results. The Food and Drug Administration Amendments Act (FDAAA) of 2007 mandated that sponsors of applicable studies must provide study flow, baseline subject characteristics, and outcomes after active and control interventions within one year of study completion.[@b8-cpaa-2-169] The FDAAA regulations defined the following clinical trials as needing to adhere to the requirements: Phase II--IV interventional studies, studies involving any drugs, biological products, or medical devices regulated by the FDA, studies having at least one site in the US or which are conducted under an investigational new drug application or investigational device exemption; and studies initiated or ongoing as of September 27, 2007, or later.[@b9-cpaa-2-169]--[@b12-cpaa-2-169] Results can be posted within three years of completion of the study for trials investigating off-label use of previously approved drugs.

Registration of clinical trials on ClinicalTrials.gov improved the transparency of clinical research tremendously. [@b13-cpaa-2-169]--[@b15-cpaa-2-169] Stakeholders can find the WHO minimum dataset for the design of 92,385 studies.[@b16-cpaa-2-169] Harvard University has recognized the achievement of this website with their Innovations in American Government Award.[@b17-cpaa-2-169] The degree of sponsor compliance with federal law in providing results of studies on ClinicalTrials.gov has not been examined as yet. We aimed to examine the completeness of the posted study designs and factors associated with reporting study results.

Methods
=======

We retrieved all closed studies from ClinicalTrials.gov as of May 20, 2010. We retrieved all 20 available fields, including the ClinicalTrials.gov identifier, age group, gender, disease status of the eligible subjects, and examined interventions, recruitment status, study sponsors, study type and design, phase of clinical trials, start and completion dates, and posting of study results. Field locations were as described online at <http://prsinfo.clinicaltrials.gov/definitions.html>. We used the exact data provided by the sponsors. We further categorized interventions as behavioral, biological, device, dietary supplements, disease management, drug, education, genetic, procedural, and exercise. We also redefined conditions into larger diagnostic categories with the first disease stated. For example, when the condition was defined as "arthralgia, pain assessment", we analyzed it under the category of "arthralgia". The available data do not have a single field to define the studies that are applicable to the US Public Law 110-85 (FDAAA), Title VIII, Section 801 for mandatory reporting of results. Therefore, we defined closed not-recruiting interventional trials, excluding Phase 0--I trials, as applicable to comply with FDAAA regulations.

We calculated descriptive frequency statistics without formal hypothesis testing because we did not sample the data but rather analyzed all closed studies available. We then compared the proportions of studies having results with the proportions of studies without results in categories of age, gender, disease status, interventions, study sponsorship, types, and completion dates. All calculations were performed with frequency procedure using SAS 9.1 software (SAS Institute Inc., Cary, NC).

Results
=======

We retrieved 57,299 records but eliminated 66 records with misplaced fields, leaving a total of 57,233 records for analysis. We analyzed the completeness of the minimum dataset and found that 393 studies did not provide the gender for eligible subjects, 287 studies did not specify the type of study, and 5908 did not specify intervention or exposure ([Table 1](#t1-cpaa-2-169){ref-type="table"}). We noticed a marked inconsistency in the classification and reporting of patient conditions, which made statistical analysis difficult. For example, "non small cell lung cancer" was reported variously as "non-small cell lung cancer", "non small cell lung carcinoma", or "NSCLC". More than 50% of the studies included adult subjects, and 85% of all studies recruited both genders. Children and seniors were included in a very small proportion of studies. More than 60% of closed studies were completed, and more than 65% of closed studies examined the effects of pharmacologic treatments. A total of 39% of all studies were sponsored by industry. Most of the studies (97%) did not have their results posted on the website.

Of 31,161 applicable closed interventional studies, 4.5% had results available. Proportions of studies with results contained similar age and gender groups ([Table 2](#t2-cpaa-2-169){ref-type="table"}). Studies with children as subjects tended to report results more frequently. Industry-sponsored studies reported results more often (8.1%) than nonindustry-funded studies ([Table 3](#t3-cpaa-2-169){ref-type="table"}). Phase III and IV clinical trials reported results more often (total 14%) compared with Phase II trials (3%, [Table 3](#t3-cpaa-2-169){ref-type="table"}). Suspended interventions (n = 414) and withdrawn interventions (n = 486) did not provide results or reasons for the cause of suspension or withdrawal ([Table 3](#t3-cpaa-2-169){ref-type="table"}). The first studies containing results (n = 3) were sponsored by Merck and added to the database in 2009. These three studies are listed as NCT00882440, NCT00886600, and NCT00887250, and were completed in 1992. Among the applicable closed interventional studies, 7446 did not provide a completion date. The proportion of the studies with results increased over time (see [Figure 1](#f1-cpaa-2-169){ref-type="fig"}).

Among the applicable 31,161 closed interventional studies, the studies of hypertension and influenza reported results more often (7.5% and 9.7%, respectively, [Table 4](#t4-cpaa-2-169){ref-type="table"}). The most commonly reported examined disease states included breast cancer, schizophrenia, and pain. Most of the closed studies of these conditions did not report the results ([Table 4](#t4-cpaa-2-169){ref-type="table"}). The proportion of studies with results varied substantially between different sponsors ([Table 5](#t5-cpaa-2-169){ref-type="table"}). Several pharmaceutical firms, including GlaxoSmithKline, Pfizer, Merck, and Eli Lilly and Company, sponsored more than 50 studies each and provided the results for more than 10% of the total sponsored studies. Two pharmaceutical firms, ie, Alcon Research and Eli Lilly and Company, provided results for more than 20% of applicable sponsored studies. Several sponsors did not provide results for funded studies. For instance, the National Cancer Institute sponsored 208 closed interventions without results and Memorial Sloan-Kettering Cancer Center sponsored 190 closed interventions without results. Genetic treatments were examined in 48 closed studies. None of the genetic studies provided results ([Table 6](#t6-cpaa-2-169){ref-type="table"}). The studies of several drug, including zidovudine, risperidone, and vildagliptin, did not report their results.

Of 31,161 applicable closed interventional studies, 2860 were terminated and 5.3% of 2860 reported results ([Table 7](#t7-cpaa-2-169){ref-type="table"}). In terminated studies, the most common diseases involved were diabetes and human immunodeficiency virus. Of the terminated studies in prostate cancer, anemia, asthma, and rheumatoid arthritis, more than 10% reported results. The terminated studies of subjects with lymphoma, pain, obesity, heart failure, and colorectal cancer did not provide results. The majority of interventions that were suspended or withdrawn examined the effects of drugs ([Table 8](#t8-cpaa-2-169){ref-type="table"}). Breast cancer and prostate cancer were among the most common conditions for trials which were suspended or had interventions withdrawn.

Discussion
==========

We found that a statistical analysis of compliance with mandatory reporting of results was difficult to perform. Missing or inconsistently reported study details, including patient diseases, study completion dates, and reported interventions may lead to wrong conclusions about a sponsor's compliance with federal law regarding study registration and reporting of outcomes. We could not identify a single well-defined field that has applicability status of individual studies to provide results. One variable provides information about the posting of the results. The changes in protocols and deviations from the planned presentation of the primary outcomes and safety outcomes were not easy to analyze without time-consuming evaluation of each study. Reporting of studies completed before September 2007 was available in a small proportion of the interventions, when the sponsors decided to comply.

Both clinicians and the general public need complete and accurate information about study protocols and results.[@b9-cpaa-2-169] Stakeholders should be able to find a clear description of interventions, including prior FDA approvals, off-label evaluations, investigational new drug applications and numbers, and investigational device exemptions, as well as the applicability of reported results.[@b18-cpaa-2-169]--[@b20-cpaa-2-169] Critical appraisal of the protocols and reported results on a regular basis by clinical epidemiologists may be worthwhile to ensure integrity of the clinical research reported on ClinicalTrials.gov. Clinicians and patients need independent access to protocols and market approval status of the tested interventions. Finally, our analysis found that none of the suspended or withdrawn studies reported either the baseline characteristics of enrolled subjects or the exact reasons for terminating the study. Posting the results of a study should be mandatory for all trials, regardless of prior FDA approval.[@b9-cpaa-2-169],[@b11-cpaa-2-169]

Our study had several limitations. We defined the applicability of studies without evaluation of the market status of individual studies. We did not analyze deviations from the protocols when reporting the results. We did not analyze whether the sponsors posted the study results in a timely manner according to the expected date. Future research should analyze time intervals between completion of the study, posting of results, and publication of the results in peer-reviewed journals.

We conclude that compliance with the requirements to post results of closed studies is low for both industry- and nonindustry-sponsored studies. The need for studies to report the results should be identified in the database during the registration of the studies.
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###### 

Distribution of the studies closed in [www.clinicaltrials.gov](www.clinicaltrials.gov) on 20 May 2010

  Category                              Frequency                        Percentage
  ------------------------------------- -------------------------------- ------------
  **Age**                                                                
  Adult                                 10,254                           17.92
  Adult/senior                          32,678                           57.1
  Child                                 3428                             5.99
  Child/adult                           2544                             4.44
  Child/adult/senior                    8158                             14.25
  Senior                                171                              0.3
  **Gender**                            Frequency missing (n = 393)      
  Both                                  48,224                           84.84
  Female                                5408                             9.51
  Male                                  3208                             5.64
  **Funding sources**                                                    
  Industry                              22,288                           38.94
  Industry with other funding sources   4835                             8.45
  **Recruitment**                                                        
  Active, not recruiting                13,751                           24.03
  Approved for marketing                16                               0.03
  Completed                             36,992                           64.63
  Enrolling by invitation               1330                             2.32
  No longer available                   24                               0.04
  Suspended                             587                              1.03
  Temporarily not available             7                                0.01
  Terminated                            3554                             6.21
  Withdrawn                             685                              1.2
  Withheld                              287                              0.5
  **Study types**                       Frequency missing (n = 287)      
  Expanded access                       47                               0.08
  Interventional                        48,859                           85.8
  Observational                         8040                             14.12
  **Recruitment**                                                        
  Active, not recruiting                13,751                           24.03
  Approved for marketing                16                               0.03
  Completed                             36,992                           64.63
  Enrolling by invitation               1330                             2.32
  No longer available                   24                               0.04
  Suspended                             587                              1.03
  Temporarily not available             7                                0.01
  Terminated                            3554                             6.21
  Withdrawn                             685                              1.2
  Withheld                              287                              0.5
  **Study results**                                                      
  Has results                           1793                             3.13
  No results available                  55,440                           96.87
  **Phases**                            Frequency missing (n = 16,589)   
  Phase 0                               176                              0.43
  Phase I                               7163                             17.62
  Phase II                              12,775                           31.43
  Phase II                              10,657                           26.22
  Phase II--II                          1182                             2.91
  Phase IV                              6488                             15.96
  Phase I--II                           2203                             5.42
  **Interventions**                     Frequency missing (n = 5908)     
  Behavioral                            3297                             6.42
  Biological                            3947                             7.69
  Device                                3303                             6.44
  Diet                                  112                              0.22
  Dietary supplement                    912                              1.78
  Disease management                    8                                0.02
  Drug                                  33,605                           65.47
  Education                             66                               0.13
  Genetic                               250                              0.49
  Other                                 1815                             3.54
  Procedure                             3688                             7.19
  Radiation                             207                              0.4
  Exercise                              115                              0.22

###### 

Age and gender distribution of the interventional, active, not recruiting studies applicable to reporting the results (Phase 0--I excluded)

  Age                  Gender                       Has results   No results available   n        Percentage with results
  -------------------- ---------------------------- ------------- ---------------------- -------- -------------------------
  Adult                Both                         151           3807                   3958     3.82
                       Female                       39            876                    915      4.26
                       Male                         6             410                    416      1.44
                       Total                        196           5093                   5289     3.71
                       Frequency missing (n = 10)                                                 
  Adult/senior         Both                         787           15,719                 16,506   4.77
                       Female                       46            1348                   1394     3.30
                       Male                         28            708                    736      3.80
                       Total                        861           17,775                 18,636   4.62
                       Frequency missing (n = 16)                                                 
  Child                Both                         157           1951                   2108     7.45
                       Female                       6             34                     40       15.00
                       Male                         0             31                     31       0.00
                       Total                        163           2016                   2179     7.48
  Child/adult          Both                         30            1066                   1096     2.74
                       Female                       10            151                    161      6.21
                       Male                         1             23                     24       4.17
                       Total                        41            1240                   1281     3.20
                       Frequency missing (n = 1)                                                  
  Child/adult/senior   Both                         113           2987                   3100     3.65
                       Female                       12            385                    397      3.02
                       Male                         4             119                    123      3.25
                       Total                        129           3491                   3620     3.56
                       Frequency missing (n = 35)                                                 
  Senior               Both                         4             82                     86       4.65
                       Female                       0             8                      8        0.00
                       Male                         0             0                      0        
                       Total                        4             90                     94       4.26

###### 

Funding distribution, phases, and completion status of the interventional, active, not recruiting studies applicable to reporting of results (Phase 0--I excluded)

  Funding source                          Has results   No results available   n        Percentage with results
  --------------------------------------- ------------- ---------------------- -------- -------------------------
  Total                                   1394          29,767                 31,161   4.47
  Industry                                1126          12,789                 13,915   8.09
  Industry with other sources             72            2644                   2716     2.65
  National Institutes of Health           23            2214                   2237     1.03
  Other/National Institutes of Health     19            1367                   1386     1.37
  Other/unknown                           15            840                    855      1.75
  Network/National Institutes of Health   2             665                    667      0.30
  US Federal                              5             444                    449      1.11
  National Institutes of Health/other     0             366                    366      0.00
  **Phases**                                                                            
  Total                                   1268          23,268                 24,536   5.17
  Phase I--II                             26            1444                   1470     1.77
  Phase II                                283           8788                   9071     3.12
  Phase II--II                            19            798                    817      2.33
  Phase II                                613           7555                   8168     7.50
  Phase IV                                327           4683                   5010     6.53
  Frequency missing (n = 6625)                                                          
  **Completion status**                                                                 
  Completed                               1243          25,390                 26,633   4.67
  Enrolling by invitation                 0             768                    768      0.00
  Suspended                               0             414                    414      0.00
  Terminated                              151           2709                   2860     5.28
  Total                                   1394          29,767                 31,161   4.47
  Withdrawn                               0             486                    486      0.00

###### 

Distribution of conditions of subjects in closed interventional, active, not recruiting studies applicable to reporting of results (Phase 0--I excluded)

  Conditions                          Has results   No results available   n        Percentage with results
  ----------------------------------- ------------- ---------------------- -------- -------------------------
  Total                               1394          29,763                 31,157   4.47
  **Largest number with results**                                                   
  Diabetes                            99            1378                   1477     6.70
  Hypertension                        35            435                    470      7.45
  Human immunodeficiency virus        33            1165                   1198     2.75
  Asthma                              30            513                    543      5.52
  **Largest number closed studies**                                                 
  Breast cancer                       16            490                    506      3.16
  Schizophrenia                       18            431                    449      4.01
  Pain                                13            342                    355      3.66
  Obesity                             4             351                    355      1.13
  Leukemia                            4             319                    323      1.24
  Lymphoma                            2             320                    322      0.62
  Prostate cancer                     12            301                    313      3.83
  Osteoarthritis                      13            245                    258      5.04
  Influenza                           25            232                    257      9.73
  Cardiovascular disease              3             233                    236      1.27
  Colorectal cancer                   2             233                    235      0.85
  Rheumatoid arthritis                12            219                    231      5.19
  Major depression                    13            206                    219      5.94
  Lung cancer                         3             216                    219      1.37
  Depression                          3             210                    213      1.41
  Anemia                              12            192                    204      5.88
  Frequency missing (n = 4)                                                         

###### 

Sponsors of the closed interventional, active, not recruiting studies applicable to reporting of results (Phase 0--I excluded)

  Sponsors                                                           Has results   No results available   n        Percentage with results
  ------------------------------------------------------------------ ------------- ---------------------- -------- -------------------------
  Total                                                              1394          29,767                 31,161   4.47
  **Largest number with the results**                                                                              
  GlaxoSmithKline                                                    115           728                    843      13.64
  Pfizer                                                             99            604                    703      14.08
  Merck                                                              93            412                    505      18.42
  Eli Lilly and Company                                              76            283                    359      21.17
  Schering-Plough                                                    43            220                    263      16.35
  Boehringer Ingelheim Pharmaceuticals                               37            181                    218      16.97
  Sanofi-aventis                                                     36            590                    626      5.75
  Alcon Research                                                     35            131                    166      21.08
  UCB Inc.                                                           33            135                    168      19.64
  Abbott                                                             25            163                    188      13.30
  Bayer                                                              23            206                    229      10.04
  Wyeth                                                              23            241                    264      8.71
  Takeda Global Research and Development Center Inc.                 21            85                     106      19.81
  **Results number of closed applicable studies**                                                                  
  Novartis Pharmaceuticals                                           5             694                    699      0.72
  AstraZeneca                                                        17            422                    439      3.87
  National Institute of Allergy and Infectious Diseases              8             386                    394      2.03
  National Heart, Lung, and Blood Institute                          6             337                    343      1.75
  Department of Veterans Affairs                                     1             324                    325      0.31
  National Institute of Mental Health                                4             239                    243      1.65
  National Cancer Institute                                          0             208                    208      0.00
  Memorial Sloan-Kettering Cancer Center/National Cancer Institute   0             190                    190      0.00
  Hoffmann-La Roche                                                  4             183                    187      2.14
  Bristol-Myers-Squibb                                               17            168                    185      9.19
  Johnson and Johnson Pharmaceutical Research and Development, LLC   7             163                    170      4.12
  Novo Nordisk                                                       12            155                    167      7.19
  National Institute of Diabetes and Digestive and Kidney Diseases   2             159                    161      1.24
  Amgen                                                              3             150                    153      1.96
  National Center for Complementary and Alternative Medicine         2             132                    134      1.49
  Astellas Pharma Inc                                                1             121                    122      0.82
  North Central Cancer Treatment Group/National Cancer Institute     0             114                    114      0.00
  National Institute on Drug Abuse                                   1             109                    110      0.91

###### 

Treatments that were examined in the closed interventional, active, not recruiting studies applicable to reporting of results (Phase 0--I excluded)

  Interventions                                               Has results   No results available   n        Percentage with results
  ----------------------------------------------------------- ------------- ---------------------- -------- -------------------------
  Total (n = 4 missing)                                       1394          29,763                 31,157   4.47
  Biological                                                  165           1740                   1905     8.66
  Device                                                      84            1914                   1998     4.20
  Drug                                                        1045          20,342                 21387    4.89
  Genetic                                                     0             48                     48       0.00
  **Interventions tested in largest number of studies**                                                     
  Topiramate                                                  0             66                     66       0.00
  Epoetin-alfa                                                0             71                     71       0.00
  Risperidone                                                 0             64                     64       0.00
  Buprenorphine                                               0             39                     39       0.00
  Zidovudine                                                  0             33                     33       0.00
  Levetiracetam                                               1             30                     31       3.23
  Aripiprazole                                                1             28                     29       3.45
  Bortezomib                                                  0             28                     28       0.00
  Etanercept                                                  1             27                     28       3.57
  Vildagliptin                                                0             28                     28       0.00
  Thalidomide                                                 0             25                     25       0.00
  Atorvastatin                                                1             23                     24       4.17
  Esomeprazole                                                1             23                     24       4.17
  Levitra/placebo                                             1             23                     24       4.17
  Pregabalin                                                  3             20                     23       13.04
  Procedure: acupuncture                                      0             23                     23       0.00
  Rituximab                                                   1             22                     23       4.35
  Nitrous oxide                                               0             21                     21       0.00
  Arsenic trioxide                                            0             20                     20       0.00
  **Interventions with largest number of reported results**                                                 
  Rotigotine                                                  9             7                      16       56.25
  Dexlansoprazole MR/dexlansoprazole MR/placebo               6             0                      6        100.00
  Pemetrexed                                                  5             8                      13       38.46
  Pemetrexed/cisplatin                                        5             4                      9        55.56
  Biological: Engerix™-B                                      4             0                      4        100.00
  Telavancin/vancomycin                                       4             0                      4        100.00
  Atomoxetine                                                 3             15                     18       16.67
  Duloxetine/placebo                                          3             7                      10       30.00

**Abbreviation:** MR, modified release.

###### 

Terminated interventional, active, not recruiting studies applicable to reporting of results (Phase 0--I excluded) by type of condition (shown for ≥20 total studies)

  Conditions                     With results   No results   n      Percentage with results
  ------------------------------ -------------- ------------ ------ -------------------------
  Total                          151            2709         2860   5.28
  Diabetes                       13             135          148    8.78
  Human immunodeficiency virus   5              94           99     5.05
  Breast cancer                  2              52           54     3.70
  Lymphoma                       0              53           53     0.00
  Schizophrenia                  2              41           43     4.65
  Prostate cancer                5              35           40     12.50
  Anemia                         5              30           35     14.29
  Pain                           0              33           33     0.00
  Leukemia                       3              29           32     9.38
  Non small cell lung cancer     7              47           54     12.96
  Obesity                        0              31           31     0.00
  Asthma                         4              24           28     14.29
  Heart failure                  0              27           27     0.00
  Colorectal cancer              0              26           26     0.00
  Osteoarthritis                 1              22           23     4.35
  Myeloma                        0              22           22     0.00
  Ovarian cancer                 1              20           21     4.76
  Rheumatoid arthritis           4              17           21     19.05
  Crohn's disease                1              19           20     5.00
  Hypertension                   1              19           20     5.00

###### 

Patient conditions in withdrawn and suspended interventions applicable to reporting of results by type of treatment (shown if ≥10 interventions). The results are not available for all studies

  Withdrawn interventions                   Biological   Device   Drug   Procedure   Radiation   Total
  ----------------------------------------- ------------ -------- ------ ----------- ----------- -------
  Total                                     20           47       341    45          2           486
  Breast cancer                             3            0        12     0           0           16
  Diabetes                                  1            0        9      2           0           12
  Asthma                                    1            1        7      2           0           11
  Human immunodeficiency virus              4            0        5      0           0           11
  **Suspended interventions**                                                                    
  Total                                     50           43       254    41          1           414
  Prostate cancer                           1            0        8      1           0           11
  Brain and central nervous system tumors   2            0        8      0           0           10
  Human immunodeficiency virus              1            0        8      1           0           10
  Leukemia                                  3            0        6      1           0           10
  Melanoma                                  6            0        4      0           0           10
